Anti-CD22 CAR-T Therapy for CD19-refractory or Resistant Lymphoma Patients
Status:
Unknown status
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to study the feasibility and efficacy of
anti-CD22:TCRz:4-1BB chimeric antigen receptor (CAR)-modified T (CAR-T) cells in treating
recurrent patients with refractory or resistant lymphoma to anti-CD19:TCRz:CD28 CAR-T cells.
Recently, cancer immunotherapy, treatments aiming to arm patients with immunity specifically
against cancer cells, has emerged as a promising therapeutic strategy. Among the many
emerging immunotherapeutic approaches, clinical trials utilizing CARs against B cell
malignancies have demonstrated remarkable potential. CARs combine the variable region of an
antibody with T-cell signaling moieties to confer T-cell activation with the targeting
specificity of an antibody. Thus, CARs are not MHC-restricted so they are not vulnerable to
MHC down regulation by tumors. However, defined by the recession of evaluable lesions, the
persistence and efficacy of CAR-T cells are still restricted by the "target" selection.
Previous clinical studies largely utilized CD19 for the in vivo targeting of CAR-T cells,
which preferentially become refractory or resistant due to the heterogeneity of lymphoma.
This clinical investigation is to test a hypothesis whether anti-CD22 CAR-T cells work more
effective in lymphoma patients refractory or resistent to anti-CD19:TCRz:CD28 CAR-T cells.